Prior view was $22.50-$24.00, consensus $23.23. Jazz Pharmaceuticals (JAZZ) is updating its full year 2025 financial guidance primarily to reflect the impact of the Chimerix acquisition and certain Xyrem antitrust litigation settlements.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals reports Q1 adjusted EPS $1.68 vs. $2.63 last year
- Jazz Pharmaceuticals backs FY25 revenue view $4.15B-$4.4B, consensus $4.29B
- Appeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fight
- Jazz Pharmaceuticals (JAZZ) Q1 Earnings Cheat Sheet
- Jazz Pharmaceuticals receives CHMP positive opinion for zanidatamab